Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

• Recombinant human thrombopoietin (rhTPO) promotes platelet engraftment in patients after allogeneic hematopoietic stem cell transplantation;• The 3-year OS rate of patients with poor platelet graft function (PPGF) was significantly less than that of patients with good platelet graft function ( GPGF);• In patients with myelodysplastic syndromes (MDS) and aplastic anemia (AA), rhTPO was associated with a significant survival advantage.

Source: Biology of Blood and Marrow Transplantation - June 19, 2017 Category: Hematology Authors: Hong Wang, Man Huang, Ying Zhao, Jia-Qian Qi, Chun Chen, Ya-Qiong Tang, Hui-Ying Qiu, Cheng-Cheng Fu, Xiao-Wen Tang, De-Pei Wu, Chang-Geng Ruan, Yue Han Source Type: research